Vitamin Shoppe Inc
Charlotte’s Web: What to Expect from Q3 Earnings
Charlotte’s Web Holdings (CWEB) (CWBHF) will report third-quarter earnings before the market opens on November 13. Let’s look at analysts’ expectations.
Why Wall Street Has a ‘Buy’ Rating on Herbalife Stock
Herbalife (HLF) impressed investors with its financial performance in the first nine months of 2018.
Herbalife Beats Q3 Estimates and Reports Robust Growth
Herbalife stock (HLF) rose 1.6% in after-hours trading following the company’s robust third-quarter results on October 30.
Does Herbalife Stock Have Room for More Growth?
So far, Herbalife (HLF) shares have had a phenomenal run in 2018. Herbalife stock has risen 61.5% on a YTD basis as of September 25.
What Analysts Recommend for Herbalife Stock after Q2 2018
Herbalife (HLF) impressed with its performance in the first half of 2018.
Will Herbalife’s Strong Q2 2018 Results Lift Its Stock?
Shares of Herbalife rose 2.6% in after-hours trading following the company’s stronger-than-expected second-quarter results on August 1.
What Analysts Recommend for Herbalife Stock
Herbalife Nutrition (HLF) sustained its growth momentum in 1Q18 and reported strong results.
Could Herbalife Stock’s Bullishness Continue?
Herbalife Nutrition (HLF) stock has followed a strong uptrend due to improving fundamentals.
Analyst Recommendations for Herbalife Stock after 4Q17
Herbalife’s bottom line improved due to the timing shift in expenses, favorable currency rates, and a lower adjusted effective tax rate.
Herbalife’s 4Q17 Sales Beat Estimate, Returned to Growth
Herbalife’s (HLF) top line returned to growth in 4Q17 due to its strong performance in China and the EMEA.
Herbalife Crushed 4Q17 Earnings Estimate, Marking 29% Growth
Herbalife (HLF) reported better-than-expected 4Q17 EPS on February 22, 2018. Its 4Q17 adjusted EPS was $1.29.
Why Herbalife Stock Fell despite Strong 4Q17 Results
Herbalife (HLF) reported better-than-expected 4Q17 results on February 22, 2018, exceeding analysts’ expectations.
Analyst Recommendations for Herbalife before 4Q17
Of the analysts covering Herbalife (HLF) stock, 50% of them are recommending a “buy,” and 50% are recommending a “hold.”
What to Expect from Herbalife’s 4Q17 Sales
Analysts expect Herbalife’s (HLF) top line to return to growth in 4Q17, with sales of $1.1 billion, a 3.3% rise YoY.
Could Lower Volumes, Higher Cost Hurt Herbalife’s 4Q17 Earnings?
Wall Street analysts expect Herbalife’s (HLF) adjusted earnings for 4Q17 to be $0.96 per share, which represents a YoY decline of 4%.
Can Herbalife’s 4Q Earnings Stall Breakneck Pace of Its Stock?
Herbalife (HLF) will announce its 4Q17 earnings on February 22. Analysts expect a YoY decline, reflecting weak volumes and margin headwinds.
How Herbalife’s Earnings Are Looking for 2018
The declining volumes across the majority of Herbalife’s (HLF) markets have adversely impacted the company’s earnings.
How Herbalife’s Sales Could Mark an Improvement in 2018
Herbalife (HLF) has been disappointing investors with its sales performance. The company’s top line has fallen for the past four quarters.
Can Herbalife Stock Continue Its Uptrend in 2018?
Herbalife (HLF) stock soared 40.7% in 2017, riding a boost from the increase in stake by activist investor Carl Icahn in the first quarter.
What Analysts Are Recommending for Herbalife Stock
The majority of analysts providing recommendations for Herbalife (HLF) are maintaining a “neutral” outlook.
Herbalife: 3Q17 Sales Fell Year-over-Year, Missed Estimates
Herbalife’s (HLF) sales of $1.1 billion in 3Q17 missed analysts’ estimate and fell 3.3% on a YoY (year-over-year) basis. The company’s volume points fell across its key markets.
Here’s Why Herbalife Missed 3Q17 Earnings Estimate
Herbalife (HLF) reported weaker-than-expected 3Q17 EPS (earnings per share) on Thursday, November 2, 2017. Its adjusted EPS of $0.82 was below analysts’ estimate of $0.88.
Herbalife Disappoints in 3Q17, Stock Falls
Herbalife (HLF) stock reported sluggish 3Q17 results, and then the stock fell 3.9% in after-hours trading. Its sales and profitability fell YoY and missed the consensus estimates.
Company & Industry Overviews
Herbalife Announces Share Buyback: Stock Jumps 9.8%
Herbalife (HLF) stock rose 9.8% and closed at $68.04 on Monday following the company’s announcement of a buyback of $600.0 million worth of its own shares.
Herbalife: Analysts’ Recommendations after 2Q17
Most of the analysts covering Herbalife (HLF) stock continue to maintain a neutral outlook. However, analysts might downgrade the stock.
Analyzing Herbalife’s 2Q17 Earnings Beat
Herbalife’s adjusted EPS (earnings per share) of $1.51 surpassed analysts’ estimate of $1.12 and rose 17.1%—compared to 2Q16.
Herbalife Stock Fell after Its 2Q17 Results
On August 1, Herbalife (HLF) stock fell ~4% in after-hour trading following its mixed 2Q17 results and bleak outlook.
Herbalife: Analysts’ Recommendations and Target Price
Most of the analysts covering Herbalife (HLF) stock maintain a “neutral” outlook. The company’s top line is expected to fall in 2Q17.
Company & Industry Overviews
Herbalife Expects Higher EPS and Lower Sales in 2017
Herbalife (HLF) raised its 2Q17 EPS (earnings per share) guidance. The company expects its adjusted 2Q17 EPS to be $0.95–$1.15.
Will Analysts Change Their Rating on Herbalife Stock?
Most of the analysts covering Herbalife are neutral on the stock. However, this could change following the company’s better-than-expected 1Q17 results.
Why Herbalife’s 1Q17 Sales Fell despite Beating Estimates
Herbalife’s (HLF) 1Q17 sales of $1.1 billion beat analysts’ estimate but fell ~2% on a YoY (year-over-year) basis.
What Analysts Think of Herbalife Stock
On April 27, 2017, Herbalife was trading at $62.94, reflecting a 7.8% upside to analysts’ 12-month price target of $68.25 per share.
Must-know: Davidson Kempner disposes position in Apple
Apple saw its shares soar in April after it expanded its share repurchase program to $90 billion from the $60 billion level announced last year.
Why Davidson Kempner adds new position in Vitamin Shoppe
Vitamin Shoppe said in its annual filing that the Vitamins, Minerals, and Supplements (VMS) industry in the U.S. is highly fragmented.
Why Davidson Kempner initiates new position in Brunswick Corp.
Brunswick is a leading global designer, manufacturer, and marketer of recreation products including marine engines, boats, fitness equipment, and bowling and billiards equipment.
Davidson Kempner adds convertible bond position in Alpha Natural Resources
Despite the challenging conditions for the coal industry, ANR beat estimates for 1Q14.
Must-know: Davidson Kempner exits position in Perrigo
Perrigo acquired Irish biotech company Elan last year for $8.6 billion.
Davidson Kempner Capital Management’s 1Q14 positions
The company’s reportable first quarter portfolio totaled $2.20 billion— down from $ 2.59 billion in the 4Q13.